JP2017507160A5 - - Google Patents

Download PDF

Info

Publication number
JP2017507160A5
JP2017507160A5 JP2016555752A JP2016555752A JP2017507160A5 JP 2017507160 A5 JP2017507160 A5 JP 2017507160A5 JP 2016555752 A JP2016555752 A JP 2016555752A JP 2016555752 A JP2016555752 A JP 2016555752A JP 2017507160 A5 JP2017507160 A5 JP 2017507160A5
Authority
JP
Japan
Prior art keywords
alkyl
optionally substituted
amino
aryl
cyano
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016555752A
Other languages
English (en)
Japanese (ja)
Other versions
JP6574435B2 (ja
JP2017507160A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/019535 external-priority patent/WO2015134998A1/en
Publication of JP2017507160A publication Critical patent/JP2017507160A/ja
Publication of JP2017507160A5 publication Critical patent/JP2017507160A5/ja
Priority to JP2019149385A priority Critical patent/JP6915003B2/ja
Application granted granted Critical
Publication of JP6574435B2 publication Critical patent/JP6574435B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016555752A 2014-03-07 2015-03-09 ヒト血漿カリクレイン阻害剤 Active JP6574435B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2019149385A JP6915003B2 (ja) 2014-03-07 2019-08-16 ヒト血漿カリクレイン阻害剤

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201461949808P 2014-03-07 2014-03-07
US61/949,808 2014-03-07
US201461981515P 2014-04-18 2014-04-18
US61/981,515 2014-04-18
PCT/US2015/019535 WO2015134998A1 (en) 2014-03-07 2015-03-09 Human plasma kallikrein inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019149385A Division JP6915003B2 (ja) 2014-03-07 2019-08-16 ヒト血漿カリクレイン阻害剤

Publications (3)

Publication Number Publication Date
JP2017507160A JP2017507160A (ja) 2017-03-16
JP2017507160A5 true JP2017507160A5 (OSRAM) 2018-08-09
JP6574435B2 JP6574435B2 (ja) 2019-09-11

Family

ID=54055948

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2016555752A Active JP6574435B2 (ja) 2014-03-07 2015-03-09 ヒト血漿カリクレイン阻害剤
JP2019149385A Active JP6915003B2 (ja) 2014-03-07 2019-08-16 ヒト血漿カリクレイン阻害剤
JP2021116716A Pending JP2021169499A (ja) 2014-03-07 2021-07-14 ヒト血漿カリクレイン阻害剤
JP2023189564A Pending JP2023181543A (ja) 2014-03-07 2023-11-06 ヒト血漿カリクレイン阻害剤

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2019149385A Active JP6915003B2 (ja) 2014-03-07 2019-08-16 ヒト血漿カリクレイン阻害剤
JP2021116716A Pending JP2021169499A (ja) 2014-03-07 2021-07-14 ヒト血漿カリクレイン阻害剤
JP2023189564A Pending JP2023181543A (ja) 2014-03-07 2023-11-06 ヒト血漿カリクレイン阻害剤

Country Status (33)

Country Link
US (14) US10125102B2 (OSRAM)
EP (4) EP3113772B8 (OSRAM)
JP (4) JP6574435B2 (OSRAM)
KR (2) KR102736869B1 (OSRAM)
CN (2) CN113307772B (OSRAM)
AU (3) AU2015226855C1 (OSRAM)
BR (1) BR112016020199A8 (OSRAM)
CA (2) CA3164693A1 (OSRAM)
CY (2) CY1123810T1 (OSRAM)
DK (2) DK3113772T3 (OSRAM)
EA (1) EA036251B1 (OSRAM)
ES (3) ES3039514T3 (OSRAM)
FR (1) FR21C1048I2 (OSRAM)
HR (2) HRP20221373T1 (OSRAM)
HU (3) HUE060660T2 (OSRAM)
IL (2) IL280785B2 (OSRAM)
LT (3) LT3828173T (OSRAM)
LU (1) LUC00233I2 (OSRAM)
MA (1) MA53399B1 (OSRAM)
MX (2) MX377845B (OSRAM)
MY (1) MY199131A (OSRAM)
NL (1) NL301142I2 (OSRAM)
NO (1) NO2022046I1 (OSRAM)
NZ (2) NZ724250A (OSRAM)
PH (1) PH12016501750B1 (OSRAM)
PL (2) PL3828173T3 (OSRAM)
PT (2) PT3113772T (OSRAM)
RS (2) RS61159B1 (OSRAM)
SG (2) SG10202001795XA (OSRAM)
SI (1) SI3113772T1 (OSRAM)
SM (2) SMT202100031T1 (OSRAM)
WO (1) WO2015134998A1 (OSRAM)
ZA (1) ZA201606320B (OSRAM)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6479763B2 (ja) 2013-03-25 2019-03-06 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 第ｘｉａ因子阻害剤としての置換アゾール含有のテトラヒドロイソキノリン
GB2517908A (en) 2013-08-14 2015-03-11 Kalvista Pharmaceuticals Ltd Bicyclic inhibitors
TWI636047B (zh) 2013-08-14 2018-09-21 英商卡爾維斯塔製藥有限公司 雜環衍生物
UY35971A (es) 2014-01-31 2015-07-31 Bristol Myers Squibb Company Una Corporación Del Estado De Delaware Macrociclos con grupos p2? aromáticos como inhibidores del factor xia
NO2760821T3 (OSRAM) 2014-01-31 2018-03-10
DK3113772T3 (da) 2014-03-07 2020-12-07 Biocryst Pharm Inc Trifluormethylsubstituerede pyrazoler som inhibitorer af kallikrein fra humant plasma
CN107074821B (zh) 2014-09-04 2020-05-22 百时美施贵宝公司 为fxia抑制剂的二酰胺大环化合物
US9453018B2 (en) 2014-10-01 2016-09-27 Bristol-Myers Squibb Company Pyrimidinones as factor XIa inhibitors
GB201421085D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd New enzyme inhibitors
GB201421083D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd Enzyme inhibitors
PL3355890T3 (pl) * 2015-10-01 2022-02-21 Biocryst Pharmaceuticals, Inc. Inhibitory ludzkiej kalikreiny osoczowej
HRP20201131T1 (hr) 2016-05-31 2020-10-30 Kalvista Pharmaceuticals Limited Derivati pirazola kao inhibitori kalikreina plazme
GB201609603D0 (en) 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-[(6-cyano-2-fluoro-3-methoxyphenyl)Methyl]-3-(methoxymethyl)-1-({4-[(2-ox opyridin-1-YL)Methyl]phenyl}methyl)pyrazole-4-carboxamide
GB201609607D0 (en) 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts
GB201721515D0 (en) * 2017-12-21 2018-02-07 Kalvista Pharmaceuticals Ltd Dosage forms comprising a plasma kallikrein inhibtor
GB201719881D0 (en) 2017-11-29 2018-01-10 Kalvista Pharmaceuticals Ltd Solid forms of plasma kallikrein inhibitor and salts thereof
DK3716952T3 (da) 2017-11-29 2022-03-14 Kalvista Pharmaceuticals Ltd Doseringsformer omfattende en plasmakallikrein-inhibitor
WO2020041301A1 (en) 2018-08-20 2020-02-27 Achillion Pharmaceuticals, Inc. Pharmaceutical compounds for the treatment of complement factor d medical disorders
US11814391B2 (en) 2018-09-06 2023-11-14 Achillion Pharmaceuticals, Inc. Macrocyclic compounds for the treatment of medical disorders
UY38438A (es) * 2018-11-02 2020-05-29 Biocryst Pharm Inc Sales cristalinas de un inhibidor de calicreína plasmática
US11034669B2 (en) 2018-11-30 2021-06-15 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
JP7668227B2 (ja) * 2019-04-08 2025-04-24 バイオクライスト ファーマシューティカルズ， インコーポレイテッド 血漿カリクレイン阻害剤および眼障害におけるその使用方法
WO2021025969A1 (en) 2019-08-02 2021-02-11 Teva Pharmaceuticals International Gmbh Solid state forms of berotralstat
CR20220092A (es) * 2019-08-06 2022-06-03 Biocryst Pharm Inc Síntesis de un inhibidor de calicreína plasmática a escala de proceso
WO2021028645A1 (en) 2019-08-09 2021-02-18 Kalvista Pharmaceuticals Limited Plasma kallikrein inhibitors
CN114258392A (zh) * 2019-08-21 2022-03-29 卡尔维斯塔制药有限公司 酶抑制剂
TW202144331A (zh) * 2020-02-13 2021-12-01 德商百靈佳殷格翰國際股份有限公司 作為血漿激肽釋放酶抑制劑之雜芳族甲醯胺衍生物
US20250197403A1 (en) 2020-02-20 2025-06-19 Achillion Pharmaceuticals, Inc. Heteroaryl compounds for treatment of complement factor d mediated disorders
CN115210230A (zh) * 2020-03-04 2022-10-18 南京明德新药研发有限公司 杂环类化合物
JP7776453B2 (ja) * 2020-06-16 2025-11-26 メルク・シャープ・アンド・ドーム・エルエルシー 血漿カリクレイン阻害剤
CN116157154A (zh) * 2020-07-10 2023-05-23 默沙东有限责任公司 血浆激肽释放酶抑制剂
WO2022060842A1 (en) * 2020-09-15 2022-03-24 The Trustees Of Columbia University In The City Of New York Systems and methods for predicting graft dysfunction with exosome proteins
KR20230152692A (ko) 2021-02-02 2023-11-03 리미널 바이오사이언시스 리미티드 Gpr84 길항제 및 이의 용도
CN116375648A (zh) * 2023-03-22 2023-07-04 苏州农平科技发展有限公司 贝罗司他中间体的制备方法
WO2025122555A1 (en) * 2023-12-05 2025-06-12 Valo Health, Inc. S1p 1 receptor agonists and uses thereof

Family Cites Families (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4559157A (en) 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
LU84979A1 (fr) 1983-08-30 1985-04-24 Oreal Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux
LU86084A1 (fr) 1985-09-20 1987-04-02 Faco Sa Apparei de massage electrique
US5102417A (en) 1985-11-07 1992-04-07 Expandable Grafts Partnership Expandable intraluminal graft, and method and apparatus for implanting an expandable intraluminal graft
DE3633840A1 (de) 1986-10-04 1988-04-14 Hoechst Ag Phenylpyrazolcarbonsaeurederivate, ihre herstellung und verwendung als pflanzenwachstumsregulatoren und safener
US4800882A (en) 1987-03-13 1989-01-31 Cook Incorporated Endovascular stent and delivery system
US4820508A (en) 1987-06-23 1989-04-11 Neutrogena Corporation Skin protective composition
US4886062A (en) 1987-10-19 1989-12-12 Medtronic, Inc. Intravascular radially expandable stent and method of implant
US4992478A (en) 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
WO1990013332A1 (en) 1989-05-11 1990-11-15 Cedars-Sinai Medical Center Stent with sustained drug delivery
WO1991012779A1 (en) 1990-02-28 1991-09-05 Medtronic, Inc. Intralumenal drug eluting prosthesis
US5429634A (en) 1993-09-09 1995-07-04 Pdt Systems Biogenic implant for drug delivery and method
US5419760A (en) 1993-01-08 1995-05-30 Pdt Systems, Inc. Medicament dispensing stent for prevention of restenosis of a blood vessel
US6774278B1 (en) 1995-06-07 2004-08-10 Cook Incorporated Coated implantable medical device
EP0946508B1 (en) * 1996-12-23 2009-09-23 Bristol-Myers Squibb Pharma Company NITROGEN CONTAINING HETEROAROMATICS AS FACTOR Xa INHIBITORS
US6020357A (en) * 1996-12-23 2000-02-01 Dupont Pharmaceuticals Company Nitrogen containing heteroaromatics as factor Xa inhibitors
ZA985247B (en) 1997-06-19 1999-12-17 Du Pont Merck Pharma Guanidine mimics as factor Xa inhibitors.
PT991625E (pt) * 1997-06-19 2005-10-31 Bristol Myers Squibb Pharma Co Inibidores de factor xa com um grupo de especificidade p1 neutro
US6339099B1 (en) * 1997-06-20 2002-01-15 Dupont Pharmaceuticals Company Guanidine mimics as factor Xa inhibitors
US6271237B1 (en) * 1997-12-22 2001-08-07 Dupont Pharmaceuticals Company Nitrogen containing heteromatics with ortho-substituted P1s as factor Xa inhabitors
JP2001526268A (ja) * 1997-12-22 2001-12-18 デュポン ファーマシューティカルズ カンパニー Ｘａ因子阻害剤としての、オルト−置換Ｐ１を有する、窒素含有複素環式芳香族化合物
CN1230421C (zh) * 1999-02-10 2005-12-07 三菱制药株式会社 酰胺化合物及其药物用途
ES2197092T3 (es) 1999-04-02 2004-01-01 Bristol-Myers Squibb Pharma Company Sulfonil arilos como inhibidores del factor xa.
US20010044445A1 (en) 1999-04-08 2001-11-22 Bamaung Nwe Y. Azole inhibitors of cytokine production
US6632815B2 (en) 1999-09-17 2003-10-14 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa
US6329527B1 (en) 1999-10-21 2001-12-11 Bristol-Myers Squibb Pharma Company Synthesis of 1,3,5-trisubstituted pyrazoles
AU2001273040A1 (en) * 2000-06-27 2002-01-08 Du Pont Pharmaceuticals Company Factor xa inhibitors
EA005520B1 (ru) 2000-06-27 2005-04-28 Лабораториос С.А.Л.В.А.Т.,С.А. Карбаматы, полученные из арилалкиламинов
EP1366045A2 (en) 2000-09-22 2003-12-03 Bristol-Myers Squibb Pharma Company Efficient process for the preparation of a factor xa inhibitor
IL157873A0 (en) 2001-04-12 2004-03-28 Hoffmann La Roche DIHYDRO-BENZO [b] [1,4] DIAZEPIN-2-ONE DERIVATIVES AS MGLUR2 ANTAGONISTS II
JP4448327B2 (ja) * 2001-08-13 2010-04-07 イー・アイ・デュポン・ドウ・ヌムール・アンド・カンパニー 新規置換１ｈ−ジヒドロピラゾール、それらの製造および使用
TWI325302B (en) 2001-08-13 2010-06-01 Du Pont Benzoxazinone compounds
TWI283164B (en) 2001-09-21 2007-07-01 Du Pont Anthranilamide arthropodicide treatment
BR0212799A (pt) * 2001-09-21 2004-08-03 Du Pont Composto, composição e método para o controle de pragas invertebradas
US7030141B2 (en) * 2001-11-29 2006-04-18 Christopher Franklin Bigge Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade
TW200302225A (en) 2001-12-04 2003-08-01 Bristol Myers Squibb Co Substituted amino methyl factor Xa inhibitors
TW200303309A (en) 2001-12-04 2003-09-01 Bristol Myers Squibb Co Novel n-[4-(1h-imidazol-1-yl)-2-fluorophenyl]-3-trifluoromethyl)-1h-pyrazole-5-carboxamides as factor Xa inhibitors
US20060148858A1 (en) 2002-05-24 2006-07-06 Tsuyoshi Maekawa 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity
JP4287816B2 (ja) * 2002-06-13 2009-07-01 イー・アイ・デュポン・ドウ・ヌムール・アンド・カンパニー ピラゾールカルボキサミド殺虫剤
DE10229070A1 (de) * 2002-06-28 2004-01-15 Merck Patent Gmbh Phenylderivate 5
US6770729B2 (en) 2002-09-30 2004-08-03 Medtronic Minimed, Inc. Polymer compositions containing bioactive agents and methods for their use
JP2006516656A (ja) 2003-01-28 2006-07-06 アヴェンティス ファーマ エス．エー． Ｎ−アリールヘテロ芳香族物質、それを含む組成物およびその用途
WO2005023761A2 (en) 2003-09-11 2005-03-17 Kemia, Inc. Cytokine inhibitors
WO2005094805A1 (ja) * 2004-04-01 2005-10-13 Institute Of Medicinal Molecular Design. Inc. イミン誘導体及びアミド誘導体
RU2006139953A (ru) 2004-04-13 2008-05-20 Е.И. Дюпон Де Немур Энд Компани (Us) Антраниламидные инсектициды
WO2005113522A1 (en) 2004-05-07 2005-12-01 Janssen Pharmaceutica, N.V. Azole carboxamide inhibitors of bacterial type iii protein secretion systems
US20060069270A1 (en) 2004-09-27 2006-03-30 Rafael Shapiro Process for the preparation of 1,3,5-trisubstituted pyrazoles via [3+2] cycloaddition
US7381732B2 (en) 2004-10-26 2008-06-03 Bristol-Myers Squibb Company Pyrazolobenzamides and derivatives as factor Xa inhibitors
US20090133318A1 (en) 2004-11-18 2009-05-28 George Philip Lahm Anthranilamide insecticides
CA2588633A1 (en) * 2004-12-07 2006-06-15 Toyama Chemical Co., Ltd. Novel anthranilic acid derivative or salt thereof
US20070060589A1 (en) 2004-12-21 2007-03-15 Purandare Ashok V Inhibitors of protein arginine methyl transferases
GB0516703D0 (en) 2005-08-15 2005-09-21 Syngenta Participations Ag Novel insecticides
KR101315574B1 (ko) 2005-10-14 2013-10-08 스미또모 가가꾸 가부시끼가이샤 히드라지드 화합물 및 이의 살충 용도
JP5186751B2 (ja) * 2005-10-14 2013-04-24 住友化学株式会社 ヒドラジド化合物およびその有害生物防除用途
AR056582A1 (es) 2005-10-28 2007-10-10 Lilly Co Eli COMPUESTOS DE PIRAZOLIL UREA CON ACTIVIDAD INHIBITORIA DE CINASA P38 Y FORMULACIoN FARMACÉUTICA QUE LO COMPRENDE
CA2641441A1 (en) 2006-02-09 2007-08-23 Athersys, Inc. Pyrazoles for the treatment of obesity and other cns disorders
MX2008014499A (es) * 2006-05-16 2008-11-27 Boehringer Ingelheim Int Prolinamidas sustituidas, su perparacion y su uso como medicamentos.
US7910747B2 (en) 2006-07-06 2011-03-22 Bristol-Myers Squibb Company Phosphonate and phosphinate pyrazolylamide glucokinase activators
US7625944B2 (en) 2006-07-31 2009-12-01 Activesite Pharmaceuticals, Inc. Inhibitors of plasma kallikrein
CN101495468A (zh) * 2006-07-31 2009-07-29 艾克提弗赛特制药股份有限公司 血浆激肽释放酶抑制剂
US8188113B2 (en) 2006-09-14 2012-05-29 Deciphera Pharmaceuticals, Inc. Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
US20120225057A1 (en) 2006-10-11 2012-09-06 Deciphera Pharmaceuticals, Llc Methods and compositions for the treatment of myeloproliferative diseases and other proliferative diseases
KR20120049397A (ko) 2006-11-03 2012-05-16 노파르티스 아게 단백질 키나제 억제제로서의 화합물 및 조성물
EP2121621B1 (en) * 2006-12-08 2014-05-07 Exelixis Patent Company LLC Lxr and fxr modulators
EP2137158A4 (en) 2007-02-28 2012-04-18 Methylgene Inc LOW-MOLECULAR INHIBITORS OF PROTEINARGININE METHYLTRANSFERASES (PRMTS)
CN101298451B (zh) 2007-04-30 2013-01-30 中国中化股份有限公司 苯甲酰胺类化合物及其应用
WO2008134969A1 (fr) 2007-04-30 2008-11-13 Sinochem Corporation Composés benzamides et leurs applications
WO2010069502A2 (de) * 2008-12-18 2010-06-24 Bayer Cropscience Ag Tetrazolsubstituierte anthranilsäureamide als pestizide
ES2402887T3 (es) 2009-03-26 2013-05-10 Syngenta Participations Ag Compuestos insecticidas
US8946204B2 (en) 2009-05-07 2015-02-03 Gruenenthal Gmbh Substituted phenylureas and phenylamides as vanilloid receptor ligands
CN102762203A (zh) 2009-12-18 2012-10-31 艾克提弗赛特制药股份有限公司 血浆激肽释放酶抑制剂的前药
EP2531502B1 (en) 2010-02-01 2014-04-02 Cancer Research Technology Limited 1-(5-tert-butyl-2-phenyl-2h-pyrazol-3-yl)-3-[2-fluoro-4-(1-methyl-2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridin-7-yloxy)-phenyl]-urea and related compounds and their use in therapy
WO2011118818A1 (ja) 2010-03-26 2011-09-29 味の素株式会社 アミジノアニリン誘導体
CN102285963B (zh) 2010-06-21 2014-04-09 中国中化股份有限公司 3-甲氧基吡唑酰胺类化合物及其应用
WO2012022487A1 (de) 2010-08-20 2012-02-23 Grünenthal GmbH Substituierte cyclische carboxamid- und harnstoff-derivate als liganden des vanilloid-rezeptors
BR112013010768A2 (pt) 2010-11-10 2016-07-12 Gruenenthal Gmbh derivados de ureia e carboxamida substituídos por heteroaromáticos como ligantes dos receptores vaniloides
US9284298B2 (en) 2011-04-11 2016-03-15 Nerviano Medical Sciences S.R.L. Pyrazolyl-pyrimidine derivatives as kinase inhibitors
WO2012142308A1 (en) * 2011-04-13 2012-10-18 Activesite Pharmaceuticals, Inc. Prodrugs of inhibitors of plasma kallikrein
WO2013036232A2 (en) 2011-09-08 2013-03-14 Deciphera Pharmaceuticals, Llc Methods and compositions for the treatment of myeloproliferative diseases and other proliferative diseases
WO2013068464A1 (en) 2011-11-09 2013-05-16 Grünenthal GmbH Substituted pyrazolyl-based carboxamide and urea derivatives bearing a phenyl moiety substituted with an so2-containing group as vanilloid receptor ligands
CN103467380B (zh) 2013-09-29 2015-06-24 南开大学 一类取代苯基吡唑酰胺衍生物及其制备方法和应用
DK3113772T3 (da) 2014-03-07 2020-12-07 Biocryst Pharm Inc Trifluormethylsubstituerede pyrazoler som inhibitorer af kallikrein fra humant plasma
UY38438A (es) 2018-11-02 2020-05-29 Biocryst Pharm Inc Sales cristalinas de un inhibidor de calicreína plasmática
CR20220092A (es) 2019-08-06 2022-06-03 Biocryst Pharm Inc Síntesis de un inhibidor de calicreína plasmática a escala de proceso

Similar Documents

Publication Publication Date Title
JP2017507160A5 (OSRAM)
JP2021169499A5 (OSRAM)
RU2477723C2 (ru) Ингибиторы протеинкиназ (варианты), их применение для лечения онкологических заболеваний и фармацевтическая композиция на их основе
CN111848615B (zh) 吡啶酮衍生物及包含其的抗流感病毒药物组合物
JP2018526367A5 (OSRAM)
JP2018535963A5 (OSRAM)
JP2018536648A5 (OSRAM)
JP2014515349A5 (OSRAM)
HRP20221373T1 (hr) Supstituirani pirazoli kao inhibitori kalikreina u ljudskoj plazmi
JP2016515560A5 (OSRAM)
KR102519536B1 (ko) 트리시클릭 회전장애이성질체 화합물
JP2015531773A5 (OSRAM)
JP2014508811A5 (OSRAM)
JP2017512833A5 (OSRAM)
JP2017137291A5 (OSRAM)
JP2018529721A5 (OSRAM)
JP2015163632A5 (OSRAM)
JP2006528621A5 (OSRAM)
JP2018531218A5 (OSRAM)
JP2016528273A5 (OSRAM)
HRP20240557T1 (hr) Inhibitori kalikreina ljudske plazme
JP2018529690A5 (OSRAM)
BR122017005939A2 (pt) processo para a fabricação de derivados de sulfamida pirimidina
JP2017538767A5 (OSRAM)
JP2018536678A5 (OSRAM)